DiagnaMed Holdings Corp. · CSE:DMED

DiagnaMed — Investor Presentation (May 2023)

16 slides from DiagnaMed's investor presentation, May 2023

  1. Slide 1: Generative AI Healthcare Solutions Corporate Presentation

    Generative AI Corporate Presentation Healthcare Solutions May 2023 DiagnaMed Holdings Corp. 82 Richmond Street East Toronto, ON M5C 1P1 e. info@diagnamed.com t. 416-800-2684

  2. Slide 2: Forward-Looking Statements

    This presentation of DiagnaMed Holdings Corp. (“DiagnaMed”) contains "forward- looking information", which may include, but is not limited to, statements with respect to anticipated business plans or strategies of DiagnaMed, the anticipated date of completion of product developments, the timing of a

  3. Slide 3: Commercializing Generative AI Healthcare Solutions

    Commercializing Generative AI Healthcare Solutions Our Platforms CERVAI™ HEALTH GENAI Generative AI Generative AI Brain Health Platform Healthcare Applications CSE: DMED | OTCQB: DGNMF

  4. Slide 4: CERVAI Generative AI Brain Health Platform

    CERVAI™ Generative AI Brain Health Platform CSE: DMED | OTCQB: DGNMF

  5. Slide 5: Digital Brain Health Market

    +1 Billion Digital Brain Mental Health Depression, PTSD, Anxiety, etc Health Market over $375 Billion +1 Billon by 2031* Neurodegenerative Parkinson's, Alzheimer's, Brain injury, Dementia, *Source: TMR Report https://www.prnewswire.com/news- releases/digital-brain-health-market-to-exceed-value-of- C

  6. Slide 6: Problem

    Problem I have a family history of Alzheimer's There is no one-fits-all solution I'm feeling depressed for estimating, monitoring and I keep on forgetting things improving brain health. Expensive equipment and unproven intervention methods must be more reliable and scalable. CSE: DMED | OTCQB: DGNMF

  7. Slide 7: Solution CERVAI

    Solution Brain Age Brain Health Estimation Score Use of a novel Evaluate overall brain electroencephalogram health, output a patient (EEG) device and ML/AI risk score, and provide technique for predicting actionable data powered and monitoring brain age. by GPT. Brain Health CERVAI™ Brain Disorder G

  8. Slide 8: CERVAI Journey

    CERVAI™ Journey 1 How old is my brain? 2 3 1 2 3 TAKING CONTROL ESTIMATING BRAIN AGE BRAIN HEALTH REPORT Curious, depressed, neuro disorder, Schedule a visit to a CERVAI™ Report with estimated brain age family history, provider and brain health assessment 4 5 6 5 5 NEXT STEPS FOR BRAIN HEALTH EARLY

  9. Slide 9: Business Model CERVAI

    Business Model License Fees Place in up to 25,000 provider locations in North America (Primary care physicians, psychiatric & neurology clinics, senior care homes, pharmacies) Recurring Visits Patient programs offered 2-12 visits per year App Subscriptions Monthly subscription to virtual clinic digi

  10. Slide 10: Commercial Pathway

    Commercial Pathway 2024 H2-2023 H1-2023 Unlock new uses of CERVAI™ Commercialize Clinical diagnostic tool for CERVAI™ monitoring and screening of mental health, neurological and Grow provider sites, consumer brain injuries Establish CERVAI™ provider and patient awareness network Licensed physicians

  11. Slide 11: Partnerships

    Partnerships Brain Age Brain Health Development Development CSE: DMED | OTCQB: DGNMF

  12. Slide 12: HEALTH GENAI

    HEALTH GENAI Generative AI Healthcare Applications CSE: DMED | OTCQB: DGNMF

  13. Slide 13: Generative AI in the healthcare market to reach

    Generative AI in the healthcare market to reach ~ USD 17 billion by 2032* *Source: Market.us https://www.globenewswire.com/news- release/2023/04/03/2639957/0/en/Generative-AI-in- Healthcare-Market-Set-to-Reach-a-Valuation-of-USD-17-2- CSE: DMED | OTCQB: DGNMF Bn-by-2032-Data-Analysis-by-Experts-at-M

  14. Slide 14: Leveraging our experience in building generative AI

    Leveraging our experience in building generative AI HEALTH GENAI Generative AI applications to Healthcare Applications complement CERVAI™ Launched In-development and the unmet needs FORM GPT Dr. GENAI of the healthcare Healthcare providers to create forms powered by ChatGPT Enabling patients and pra

  15. Slide 15: Team

    Team Management & Advisors Board of Directors Fabio Chianelli Fabio Chianelli Chairman, CEO ,Chairman, CEO Founder, CEO - PharmaTher Founder, CEO - PharmaTher Founder, President - Revive Therapeutics Founder, President - Revive Therapeutics Dr. Bassma Ghali, PhD Ming Jang, CPA, CGA VP, Product Chief

  16. Slide 16: Capital Structure

    80,052,640 ~ 21% Capital Common Shares outstanding Insider Ownership Structure 2,000,000 Stock Options 240,000 Warrants $0.10 expires June 18, 2023 37,382,226 Common Shares are subject to escrow 1/10th released at: November 8, 2023, 2024, 2025 May 8, 2024, 2025, 2026 2/10th released at: November 8,

DiagnaMed Holdings — Investor Presentation (May 2023) on 6ix